ATLANTIS: a Phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line.
暂无分享,去创建一个
L. Paz-Ares | C. Galmarini | A. Farago | B. Drapkin | C. Kahatt | Jose Antonio Lopez-Vilarino de Ramos | R. Núñez